Company: RGBP
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022884
Chunk: 17

Company: Regen BioPharma Inc
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 2
Chunk 17
---
Item
2. MANAGEMENT’ S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

CERTAIN
FORWARD-LOOKING INFORMATION

Information
provided in this Quarterly report on Form 10Q may contain forward-looking statements within the meaning of Section 21E or Securities
Exchange Act of 1934 that are not historical facts and information. These statements represent the Company’s expectations or beliefs,
including, but not limited to, statements concerning future and operating results, statements concerning industry performance, the Company’s
operations, economic performance, financial conditions, margins and growth in sales of the Company’s products, capital expenditures,
financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that
are not statement of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current
expectations and involve various risks and uncertainties that could cause actual results and outcomes for future periods to differ materially
from any forward-looking statement or views expressed herein. The Company’s financial performance and the forward-looking statements
contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company
with the Securities and Exchange Commission. All references to” We”, “ Us”, “ Company” or the “ Company”
refer to Regen BioPharma, Inc.

Results
of Operations

Three
months and nine months ended June 30, 2025 and 2024

                                                        (Unaudited)                                                                                              
                                                        Three                                                                                                    
                                                        2025                                                                                                     
                                                        Amount                                                                                                   
  Net                                                                                                                                                            
  Revenues                                              $                            31,640        53.57        31,640        53.57      -                 0.00  
  Revenues,                                                                          27,425        46.43        27,425        46.43      -                 0.00  
  Net                                                                                59,065       100.00        59,065       100.00      -                 0.00  
  Operating                                                                                                                                                      
  Research                                                                                -         0.00        32,500        55.02      (32,500        -100.00  
  General                                                                            30,697        51.97        16,492        27.92      14,205           86.13  
  Consulting                                                                         46,624        78.94        95,